<DOC>
	<DOCNO>NCT01502397</DOCNO>
	<brief_summary>The purpose study determine whether preemptive nucleoside analogue therapy regular virologic monitoring prefer method management patient prior exposure hepatitis B vius ( HBV ) undergo rituximab-containing chemotherapy .</brief_summary>
	<brief_title>Risk Hepatitis B Reactivation Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy : A Prospective Study</brief_title>
	<detailed_description>Occult hepatitis B virus ( HBV ) reactivation document patient undergo rituximab-containing chemotherapy hepatitis B surface antigen ( HBsAg ) -negative serologic evidence prior exposure HBV . However detailed prospective study document incidence reactivation virologic serologic kinetics reactivation lacking . The investigator prospective study propose follow-up 70 patient serologic virologic parameter monitor every 4 week . Patients detectable HBV DNA start nucleoside analogue therapy . The optimal method duration monitoring also determine study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Documented HBsAgnegative without antibody hepatitis B surface antigen ( antiHBs ) Documented antiHBc ( total ) positive Concomitant liver diseases include chronic hepatitis C D infection , Wilson 's disease , autoimmune hepatitis , primary biliary cirrhosis primary sclerosing cholangitis . Significant alcohol intake ( &gt; 30 gram per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>anti-HBc</keyword>
	<keyword>HBsAg</keyword>
	<keyword>rituximab</keyword>
	<keyword>occult HBV</keyword>
</DOC>